Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887024 | 0.92 | MAPT (0.44) | ADAMTS4LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL5886832 | 0.89 | NAMPT (0.49) | ADAMTS4LMNASMN1; SMN2MAPTNAMPT | |
| SCHEMBL5887343 | 0.89 | PRMT5 (0.43) | ADAMTS4LMNAMAPTALDH1A1 | |
| SCHEMBL5886898 | 0.88 | HPGD (0.45) | LMNASMN1; SMN2MAPTTP53ALDH1A1 | |
| SCHEMBL5887548 | 0.88 | KMT2A (0.46) | LMNAMAPTTP53ALDH1A1POLB | |
| SCHEMBL5886779 | 0.88 | MAPT (0.44) | LMNASMN1; SMN2MAPTTP53ALDH1A1 | |
| SCHEMBL5886891 | 0.87 | TP53 (0.44) | LMNASMN1; SMN2MAPTTP53ALDH1A1 | |
| SCHEMBL5886722 | 0.87 | RXRA (0.46) | ADAMTS4MAPTALDH1A1 | |
| Dimethylamine SCHEMBL5887448 | 0.86 | HDAC6 (0.42) | ADAMTS4LMNAMAPTNAMPTALDH1A1 | |
| SCHEMBL5887054 | 0.86 | HDAC6 (0.46) | ADAMTS4LMNAMAPTTP53NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | ADAMTS4 2688/4885LMNA 711/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.